Strategic Partnership Leverage Eloquest Healthcare’s existing strategic alliance with InterRad Medical to target hospitals adopting SecurAcath. Sales opportunities include expanding U.S. adoption, cross-selling complementary adhesive and wound care solutions, and aligning with institutions prioritizing infection prevention and secure device stabilization.

Clinical Value Position Eloquest products as evidence-backed, easy-to-use solutions that reduce dressing changes, improve patient safety, and streamline clinician workflows. Highlight opportunities in procurement conversations with clinical teams seeking reliable, cost-conscious options that align with best practices.

Revenue Focus Target mid-sized hospital systems and ambulatory clinics with a revenue profile compatible with Eloquest’s current range of 10–25 million. Emphasize total cost of care reductions and predictability in supply needs to support budgeting and contract negotiations.

Brand Portfolio Promote the Mastisol and Detachol portfolio as complementary products to devices requiring securement and skin protection. Create bundled solutions for wound care, adhesive management, and infection prevention to broaden hospital formulary and distributor opportunities.

Market Readiness Capitalize on the focus on practical, real-world solutions by targeting clinical education and field-based demonstrations. Propose partnerships with healthcare leaders and educators to generate clinical data, case studies, and implementation playbooks that support faster trial adoption.